



Lumpy skin disease (LSD)

Epidemiological situation and vaccination in Europe

(update since LSD6)

**Standing Group of Experts on Lumpy Skin Disease in the South East
Europe region under the GF-TADs umbrella**

Seventh meeting (SGE LSD7)

18-19 October 2018, Ohrid, the Former Yugoslav Republic of Macedonia

*Dimitrios DILAVERIS
European Commission
Directorate-General for Health and Food Safety
G3 – Official controls and eradication of diseases in animals*


- **LSD occurrence and vaccination in SE Europe**
- **LSD measures at EU level**
- **European Commission support against Lumpy Skin Disease**
- **Recent Activities - Future priorities**
- **Concluding remarks**

LSD vaccination - occurrence in SE Europe

2015 LSD vaccination – occurrence in South East Europe (*situation as at Dec 2015*)

Vaccination in:

- Greece (Northern part), not full vaccine coverage every where



 Vaccination area
(not full coverage)

 LSD outbreaks as at
1 Jan -31 Dec 2015 (ADNS)

LSD vaccination – occurrence in SE Europe

2016 LSD vaccination-occurrence in South East Europe *(situation as at early 2017)*

Vaccination completed in:

- Bulgaria
- Greece (Northern part)
- Serbia
- FYROM
- Montenegro
- Kosovo
- Croatia
- Albania


Vaccination in progress in

- Southern part of continental Greece

 Vaccination Completed by end 2016 - early 2017

 Vaccination in progress

 LSD outbreaks as at 1 Jan -31 Dec 2016 (ADNS)



LSD vaccination – occurrence in SE Europe


2017 LSD vaccination – occurrence in South East Europe (*situation as at mid- October 2017*)

Vaccination completed since 2016 (annual revaccination in progress) or completion of primary vaccination:

- Bulgaria
- Greece (Northern part)
- Serbia
- FYROM
- Montenegro
- Kosovo
- Albania

Vaccination in progress in

- Southern part of continental Greece & islands
- Bosnia & Herzegovina



 Annual revaccination in progress or completion of primary vaccination

 Primary vaccination in progress

 LSD outbreaks as at 1 Jan-15 Oct 2017 (ADNS)



European Commission

LSD vaccination – occurrence in SE Europe

LSD vaccination – occurrence in South East Europe– Situation as at mid- October 2018

Vaccination (annual revaccination in progress) or completion of primary vaccination:

- Bulgaria
- Greece
- Serbia
- FYROM
- Montenegro
- Kosovo
- Albania

Vaccination in progress in

- Parts of continental Greece & islands
- Bosnia & Herzegovina (southern part)

 Annual revaccination in progress or completion of primary vaccination

 Vaccination in progress  Cease of vaccination

 LSD outbreaks as at 1 Jan-15 Oct 2018 (ADNS)



LSD vaccination in SE Europe

2015

- LSD vaccination in the ***North – Eastern Provinces of Greece***

2016

- All LSD affected countries (***Greece, Bulgaria, the former Yugoslav Republic of Macedonia, Serbia, Kosovo*, Albania, Montenegro***) implemented mass vaccination of all their cattle against LSD in their entire territory.
- ***Croatia***, not affected by LSD, became the 1st country to implement preventive vaccination of its entire country population against LSD (July 2016)

2017

- All countries in SE Europe that vaccinated against LSD in 2016 repeat vaccination in 2017 (annual revaccination + vaccination of new-born animals, campaigns completed or in progress).
- ***Bosnia and Herzegovina***, not affected by LSD, began implementing preventive vaccination against LSD since 2017 (2nd country to implement preventive vaccination after Croatia).

2018

- All countries in SE Europe that vaccinated against LSD in 2017 repeat vaccination in 2018 except Croatia (cease of vaccination in view of the favourable epidemiological situation).

NOTE :

In all cases the vaccines used in the above countries were **live, homologous vaccines against LSD** imported from outside the EU (except Turkey)



European Commission

LSD Vaccination Data Collection

Methodology

LSD vaccination 2019

Data on vaccination planning

End-Start dates

Numbers of holdings – animals

Intended vaccination coverage

Vaccine supply

(logistics –stocks)

GF-TADs
EUROPEAN COMMISSION
DG SANTE

LSD vaccination programmes in south-East Europe

Enter the completed data (Part 1 and Part 2 table 1.02) to the GF-TADs Secretariat (gf.tads@ec.europa.eu) with CC to D. Dibbern (Dibbern.DG.SAN@ec.europa.eu), by 10 October 2017

Country:
Date of report:

Contact Person
Name:
Address:
Email:

Position:
Tel:
Fax:

PART 1: DATA ON VACCINATION PLANNING FOR 2018 (INFORMATION AT COUNTRY LEVEL)

Data on numbers of animals (actual or estimated numbers for 2018)		Data on planned vaccination (actual data or estimates for 2018)					Comments
1	2	3	4	5	6	7	
Number of bovine holdings	Total number of bovine animals (heads), including newborn and imported animals	Estimated annual replacement rate (%) average proportion of animals that are replaced every year from the herd and have to be replaced by new ones	(Planned) date of start of vaccination	(Planned) date of end of vaccination	Estimated number of bovine animals (heads) that have received no LSD vaccination in the past	Estimated number of bovine animals (heads) that have received 1 LSD vaccination in the past	Estimated number of bovine animals (heads) that have received at least 2 LSD vaccinations in the past
Bovine animals include cattle and buffaloes, too (if present)							

PART 2: DATA ON THE PLANNING FOR THE SUPPLY OF LUMPY SKIN DISEASE VACCINES IN 2018 (INFORMATION AT COUNTRY LEVEL)

PLANNED PURCHASE OF VACCINES										VACCINES IN STOCK (ACTUAL OR ESTIMATED)			
10	11	12	13	14	15	16	17	18	19	20	21	22	23
Estimated number of all doses needed for the 2018 vaccination campaign in the country	Total number of vaccine doses planned to be purchased	Number of vaccine doses that will be produced in the country (excluding bivalent vaccines)	Estimated date of launch of vaccine	Estimated date of purchase	Number of vaccine doses that will be purchased by local authorities	Estimated date of purchase	Number of vaccine doses expected to be purchased privately (e.g. farmers, farmers associations, etc.)	Number of vaccine doses that may need to be provided by other sources (e.g. by the EU 100 vaccine bank)	Comments	Number of vaccine doses in stock (actual and ready for use for the 2017 vaccination campaign)	Expiry date	Comments	

LSD Vaccination Data Collection

Country replies received

Country	LSD vaccination 2018	COMMENTS
Albania	-	
Austria	✓	No LSD vaccination – National vaccine bank empty
Bosnia & Herzegovina	✓	Vaccination in high risk areas (South)
Bulgaria	✓	Mass Vaccination – Whole country
Croatia	✓	Stopped Vaccination – 33.000 doses in stock
Cyprus	-	No vaccination
Georgia	✓	Heterologous + homologous (EU vaccinebank)
Greece	✓	Mass Vaccination – Whole country
Hungary	-	National vaccine bank
Kosovo*	✓	Mass Vaccination – Whole country
Montenegro	✓	Mass Vaccination – Whole country
Romania	✓	No LSD vaccination
Russia (<i>affected areas</i>)	✓	Heterologous vaccine
Serbia	✓	Mass Vaccination – Whole country
Slovenia	✓	No vaccination. Signed agreement with Austria on emergency supply of 150.000 vaccine doses, if needed
The former Yugoslav Republic of Macedonia	✓	Mass Vaccination – Whole country
Turkey	✓	Mass Vaccination Heterologous vaccine
Ukraine	-	

LSD vaccination 2018 - Timing

Country	Start Date	End Date
Bosnia & Herzegovina	01/4/2018	Ongoing
Bulgaria	01/4/2018	31/7/2018
Georgia	01/08/2018	Ongoing
Greece	01/08/2018	Ongoing
Kosovo*	30/4/2018	30/05/2018
Montenegro	15/05/2018	16/08/2018
Russia (<i>affected areas</i>)	01/02/2018	ongoing
Serbia	01/01/2018	ongoing
The former Yugoslav Republic of Macedonia	15/3/2018	10/10/2018
Turkey	01/01/2018	29/6/2018

LSD vaccination 2017 - Numbers of animals

Country	Total animals present	Animals vaccinated	Vaccination coverage	Comments
Bosnia & Herzegovina	100.000	21.035	21 %	Homologous
Bulgaria	685.846	667.026	97,26 %	Homologous
Georgia	868.100	544.544	62,72 %	Heterol/ Homologous
Greece	723.709	352.962	48,77 %	Homologous
Kosovo*	346.668	197.424	56,94 %	Homologous
Montenegro	69835	69.261	99,18 %	Homologous
Russia (<i>affected areas</i>)	6.008.129	4.256.935	70,9%	Heterologous vaccine
Serbia	890.277	674.315	76 %	Homologous
The former Yugoslav Republic of Macedonia	176.648	167.944	95 %	Homologous
Turkey	15.460.938	14.426.209	93,3 %	Heterologous vaccine

LSD vaccination 2018 – Animals vaccinated for 1st time

Country	Total Animals present	Total Animals vaccinated	Animals Vaccinated for 1 st time	% Vaccinated for 1st time
Bosnia & Herzegovina	100.000	21.035		
Bulgaria	685.846	667.026		
Georgia	868.100	544.544	301.296	55.3%
Greece	723.709	352.962	108.783	30,8%
Kosovo*	346.668	197.424		
Montenegro	69.835	69.261	27.003	38,98%
Russia (<i>affected areas</i>)	6.008.129	4.256.935		
Serbia	890.277	674315	132.101	19,6 %
The former Yugoslav Republic of Macedonia	176.648	167.944	47.676	28.3 %
Turkey	15.460.938	14.426.209	1.867.555	12,94 %

LSD vaccination 2018 - Supply of vaccines (doses)

Country	National procurement	EU LSD vaccine bank	Other	Total doses supplied
Bosnia & Herzegovina				
Bulgaria	1.096.475	-	498.800 Donation (Austria)	1.595.275 (835.000 doses in stock)
Georgia	738.000 (Sheep Pox)	100.000 (LSD)	838000	
Greece	205.000	100.000		600.000+200.000 contract
Kosovo*		170.000		Additional vaccines in stock since 2017
Montenegro		95.000		
Russia (<i>affected areas</i>)	6.100.000			
Serbia				
The former Yugoslav Republic of Macedonia	17050	230.000		Vaccines purchased in 2017
Turkey	15.466.000			

LSD vaccination 2018 - General Remarks

(Based on replies received)

- A considerable proportion of the 2018 LSD vaccine supply needs were covered through the EU LSD vaccine bank (776.000 doses to date in 2018)
- Level of cooperation between countries on LSD supply remains high (e.g. transfer of LSD vaccines from Austria to Bulgaria)
- About **13-39 % (in most cases 20-30%)** of the vaccinated animals in 2018 received LSD vaccination for the first time in their life (newborns , imported from free areas e.t.c.)
- Live homologous vaccines were used in most countries (except Turkey –Russia – Georgia , info from present and previous GF TADs meetings)

LSD in SE Europe: Situation as at mid October 2018

LSD outbreaks in South East Europe in 2018 :

No outbreaks reported in any country of South East Europe since the beginning of 2018 (except Turkey see below)

Outbreaks in the vicinity of South East Europe in 2018 :

- **Turkey: 32 outbreaks** reported in ADNS (1 in East Thrace Region -European Turkey, April 2018)
- **Georgia: 5 outbreaks** reported in Aug-Sep 2018 (OIE, WAHIS)
- **Russia: 58 outbreaks** reported in June-Oct 2018 (OIE, WAHIS)

Commission Implementing Decisions on LSD in force

- COMMISSION IMPLEMENTING DECISION **EU (2016)/2008**, of 15 November 2016 **concerning animal health control measures relating to lumpy skin disease in certain Member States**
(amended by Commission Implementing Decisions (EU) **2017/1178** , **2017/1460** and **2018/744**)

Amendments related to zoning, refinement of measures for germinal products, holdings subject to revaccination and domestic movements of bovines after cessation of vaccination in free zones with vaccination.

- COMMISSION IMPLEMENTING DECISION **(EU) 2016/2009** of 15 November 2016 **approving the vaccination programmes against lumpy skin disease submitted by the Member States**

LSD measures at EU level

LSD zoning - Commission Implementing Dec. (EU) 2016/2008 (as amended)

Free zones with Vaccination (Part I):


- Croatia
- Bulgaria (certain areas in the North and East part)
- Greece (islands except Kerkyra and Limnos)

Infected zones (Part II):

- Continental Greece (including the islands of Limnos and Kerkyra)
- Bulgaria (excluding the "free with vaccination" zones)

 Free with
Vaccination zone

 Infected zone



European Commission support against Lumpy Skin Disease

- **EU LSD vaccine bank** (*vaccine donations to various countries in 2016-2018*)
 - Expansion – replenishment in progress (tender in progress for 1,8 million doses , <https://etendering.ted.europa.eu/general/page.html?name=home>)**
- **EU financial support**
 - *For EU Member countries* : cost of LSD homologous vaccines purchased and used through national procedures up to 1,1 EURO per dose
 - *For non EU Member countries* : reimbursement for the cost of LSD homologous vaccines purchased and used through national procedures up to 1,1 EURO per dose
- **Technical support: EUVET** (EU Veterinary Emergency Team, 7 LSD missions so far available upon request), EURL (2 proficiency tests , 2 NRL workshops, lab training e.t.c.)
- **LSD training activities**
 - LSD Sustained Technical Missions (STMs) in Ukraine and Belarus in 2018, mission in Georgia planned for early 2019**
- **Scientific support: EFSA Opinions on LSD** (2 opinions & 3 reports published so far, **latest on 16/10/2018**) <https://www.efsa.europa.eu/en/topics/topic/lumpy-skin-disease>, **2 more LSD reports expected in early 2019 and early 2020**).
- **Awareness – Regional Cooperation: GF TADs SGE, LSD Ministerial Conference in Sofia (Sep 2016) e.t.c.**

EU support against LSD

European Union Lumpy Skin Disease Vaccine Bank 2016 -2017 – October 2018 grants

Year	Country	Number of doses granted
2016	Bulgaria, Greece , the former Yugoslav Republic of Macedonia, Serbia, Kosovo*, Albania, Montenegro, Croatia	625.000
2017	Bosnia & Herzegovina, Montenegro, Greece, Albania, Kosovo*	325.000
2018	The Former Yugoslav Republic of Macedonia	230.000
	Kosovo*	170.000
	Montenegro	95.000
	Greece	100.000
	Albania	81.000
	Georgia	100.000 (+100.000 planned)
		776.000

1.726.000 doses of LSD vaccine (live-homologous) granted in 2016-2018 (until October) to various countries (EU + non EU MS)

Regional Coordination on LSD

GF TADs Standing Group of Experts on Lumpy Skin Disease in the South East Europe region under the GF-TADs umbrella

MEETINGS

- 1st Meeting, Brussels on 4-5 July 2016
- 2nd meeting, Lisbon (Portugal) on 21 September 2016
- 3rd meeting, Istanbul, (Turkey) on 12-13 December 2016
- Teleconference on LSD vaccine procurement , 23 February 2017
- 4th meeting, Paris , 24 May 2017
- 5th meeting, Budva (Montenegro), 19-20 October 2017
- **Teleconference on LSD vaccination and vaccine supply , 26 February 2018**
- **6th meeting, Paris , 23 May 2018**
- **7th meeting, Ohrid (the Former Yugoslav Republic of Macedonia), 18-19 October 2018**

EXPERT MISSIONS

First GF TADs expert mission on LSD in **Kazakhstan** (19-23 February 2018) at the request of the competent authorities of this country, to provide technical support, based on the experience gained in SE Europe.

Current state of play in the region South East Europe

For 3 years on a row (2016-2017-2018) :

➤ Coordinated vaccination control policy against LSD

Mass vaccination, with live homologous vaccines, uniformly adopted across South East Europe (EU + non EU countries, excl. Turkey) with support from the EU (vaccines from the EU vaccine bank + financial assistance for vaccine purchase)

➤ Meetings - Exchange of info

Regular meetings of GF TADs LSD SGE (at least 3 per year), report of all LSD outbreaks in SE Europe in ADNS

➤ Coordination in supply of LSD vaccines

EU financial support for purchase of LSD vaccines , vaccine grants from the EU LSD vaccine bank , transfer of national stocks of LSD vaccines (Austria & Hungary) for immediate use before expiry (Bulgaria).

Future activities

EC Priorities for LSD in SE Europe

The European Commission will continue to :

Provide:

- **technical assistance for LSD** (EUVET missions , STM missions, EU Ref. Laboratory)
- **training opportunities** (e.g. BTSF workshops) for EU and non EU Member Countries.
- Support for the **regional policy** against LSD including **vaccination** and **surveillance**
- Support for **the regional coordination and cooperation** for LSD (GF TADs meetings)

Follow closely:

- the **LSD epidemiological situation** (particularly in South East Europe + West Eurasia) to take prompt action, as and when needed (LSD entry / recurrence)
- the **scientific knowledge on LSD** (EURL-EFSA) to optimise the LSD control measures
- the **current discussions on an LSD exit strategy** with a view to:
 - **Capitalise on the achievements** of coordinated LSD vaccination policy in South East Europe in the past 3 years
 - **Minimise the risk of LSD recurrence**

Concluding remarks

- There is a **constant reduction of LSD outbreaks** in the region of South East Europe from **2016** (*7.483 outbr.*) to **2017** (*385 outbr.*) and further into **2018** (*32 outbreaks reported in Turkey*).
- The constant improvement of the LSD epidemiological situation in South East Europe reaffirms:
 - **The importance of regional approach** for LSD control
 - **The effectiveness of mass vaccination with homologous vaccines**
- In the light of the current epidemiological situation the time seems ripe for a discussion on **a possible regional LSD exit strategy** to ensure **smooth transition** to the situation before the invasion of LSD in SE Europe and **protection against possible LSD reappearance** in the future.



European
Commission

THANK YOU !!!!